{"id":2768,"company":{"country":"IL","currency":"USD","exchange":"TEL AVIV STOCK EXCHANGE","ipo":"1951-01-01","marketCap":43299.3,"name":"Teva Pharmaceutical Industries Ltd","phone":"97239267267.0","outstanding":1120.87,"symbol":"TEVA","website":"https://www.tevapharm.com/","industry":"Pharmaceuticals"},"price":12.0075,"year":2024,"month":2,"day":1,"weekday":"Thursday","title":"Analysis of Teva Pharmaceutical Industries Ltd's Historical Performance","date":"2024-02-01","url":"/posts/2024/02/01/TEVA","content":[{"section":"Introduction","text":"Teva Pharmaceutical Industries Ltd is a global pharmaceutical company that specializes in developing, manufacturing, and distributing generic and specialty medicines. To analyze its historical performance, we will compare Teva's stock performance to industry benchmarks."},{"section":"Stock Performance Overview","text":"Teva Pharmaceutical Industries Ltd's stock has experienced fluctuations over the past years. It reached its peak in July 2015, with a price of approximately $70 per share. However, since then, its value has declined significantly, touching a low point around $8 per share in December 2019. In recent years, the stock has shown some signs of recovery, but its performance remains volatile."},{"section":"Comparison to Industry Benchmarks","text":"To evaluate Teva's stock performance objectively, it is important to compare it to industry benchmarks. One widely used benchmark is the S\u0026P 500 Pharmaceutical Index, which represents the performance of pharmaceutical companies. Additionally, the NASDAQ Biotechnology Index can provide insights into the performance of biotech companies, which may be relevant for Teva Pharmaceutical Industries Ltd as well due to its specialty medicines portfolio."},{"section":"Analysis of Performance","text":"Over the analyzed period, Teva Pharmaceutical Industries Ltd's stock performance has generally underperformed both the S\u0026P 500 Pharmaceutical Index and the NASDAQ Biotechnology Index. The decline in Teva's stock price from its peak in 2015 to its low point in 2019 was steeper compared to the overall performance of the industry benchmarks during the same period. Although there have been occasional periods of recovery, the stock has struggled to regain its previous value."},{"section":"Factors Affecting Performance","text":"Several factors have influenced Teva Pharmaceutical Industries Ltd's stock performance. These include legal challenges, patent expirations for key drugs, increased competition, and regulatory issues. Additionally, the company has faced pricing pressures on generic drugs, which have impacted its revenue and profitability. The volatile nature of the pharmaceutical industry, changes in healthcare policies, and geopolitical factors also contribute to the performance fluctuations."},{"section":"Conclusion","text":"In conclusion, Teva Pharmaceutical Industries Ltd's stock performance has been relatively weak compared to industry benchmarks. While the stock has shown signs of recovery at times, it has struggled to sustain long-term growth. Various factors, both internal and external, have influenced the stock's performance, highlighting the challenges faced by the company within the pharmaceutical industry."}],"tags":["LongSignals","Long","Pharmaceuticals"],"news":[{"category":"company","date":1706720193,"headline":"Teva, GSK Put Up Bullish Fourth-Quarter Performances. Here's Where Novartis Fell Short.","id":125434538,"image":"https://media.zenfs.com/en/ibd.com/f7f1701ff4f721db8b22a74879ae08e5","symbol":"TEVA","publisher":"Yahoo","summary":"Teva stock neared a profit-taking zone Wednesday, while GSK stock bounded briefly out of a chase zone on strong fourth-quarter performances for both.","url":"https://finance.yahoo.com/m/fb803557-1120-31c9-80a4-1654c83823d3/teva%2C-gsk-put-up-bullish.html"},{"category":"company","date":1706718120,"headline":"Teva Plans to Divest Drug Ingredients Business in Next Step of Strategic Shift","id":125437176,"image":"https://s.yimg.com/ny/api/res/1.2/QJztdimynLrkmRyAsvqPOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/d5ec6850efcea8fe0c758a18efa648a0","symbol":"TEVA","publisher":"Yahoo","summary":"The company has struggled for years with enormous debts and litigation over its role in the opioid crisis.","url":"https://finance.yahoo.com/m/716a5fd6-c045-3c83-8800-2792918ccf7a/teva-plans-to-divest-drug.html"},{"category":"company","date":1706725821,"headline":"Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript","id":125437174,"image":"https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg","symbol":"TEVA","publisher":"Yahoo","summary":"TEVA earnings call for the period ending December 31, 2023.","url":"https://www.fool.com/earnings/call-transcripts/2024/01/31/teva-pharmaceutical-industries-teva-q4-2023-earnin/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1706724453,"headline":"How Teva's CEO is implementing his 'pivot to growth' strategy","id":125437175,"image":"https://s.yimg.com/ny/api/res/1.2/KzI2rrpePd3AZyrsB7SYJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-01/9d33caa0-c05e-11ee-befa-8a3f9c6f17df","symbol":"TEVA","publisher":"Yahoo","summary":"Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company confirmed it will sell its active pharmaceutical ingredients business as part of CEO Richard Francis' “pivot to growth” strategy. Teva CEO Richard Francis joins Yahoo Finance Live alongside Health Reporter Anjalee Khemlani to discuss the latest quarterly earnings report and plans for the company moving forward. Francis comments on his pivot to growth strategy: \"When I came in and we did the pivot-to-growth strategy, we looked across all the businesses at Teva. We understood, where did we want to grow? We clearly want to grow our innovative business and our generics business... The API business, TAPI, its the second largest API manufacturer in the world, it is world class. But two things we saw and analyzed it, which is, one, it's constrained being part of Teva. The global API market is an $85 billion market...\" For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino","url":"https://finance.yahoo.com/video/teva-ceo-implementing-pivot-growth-180733603.html"},{"category":"company","date":1706715005,"headline":"Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates","id":125437177,"image":"https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39","symbol":"TEVA","publisher":"Yahoo","summary":"Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.","url":"https://finance.yahoo.com/news/teva-pharmaceutical-industries-ltd-teva-153005859.html"},{"category":"company","date":1706714458,"headline":"UPDATE 1-Teva Pharm sees lower 2024 profit after large Q4 beat","id":125433375,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"TEVA","publisher":"Yahoo","summary":"Teva Pharmaceutical Industries forecast lower profit in 2024 after a strong 2023 fourth quarter which benefited from a large upfront payment from Sanofi as part of its collaboration to develop a treatment for inflammatory bowel disease.  Teva said it earned $1.00 per diluted share excluding one-time items in the October-December quarter, up from 71 cents per share a year earlier.  Sanofi, a leader in immunology, in October said it would invest $1.5 billion in the development of Teva's anti-TL1A drug with Teva receiving an upfront payment of $500 million.","url":"https://finance.yahoo.com/news/1-teva-pharm-sees-lower-152058635.html"},{"category":"company","date":1706710173,"headline":"Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections","id":125429429,"image":"https://media.zenfs.com/en/ibd.com/f7f1701ff4f721db8b22a74879ae08e5","symbol":"TEVA","publisher":"Yahoo","summary":"Teva stock dipped early Wednesday after the drugmaker issued light earnings guidance, at the midpoint, despite a strong quarterly report.","url":"https://finance.yahoo.com/m/fb803557-1120-31c9-80a4-1654c83823d3/teva-sinks-on-lackluster.html"},{"category":"company","date":1706706632,"headline":"Teva Pharma sees lower 2024 profit but higher sales after large Q4 beat","id":125437179,"image":"https://media.zenfs.com/en/reuters-finance.com/3f47eedec10ab1a07712857fd275c834","symbol":"TEVA","publisher":"Yahoo","summary":"JERUSALEM (Reuters) -Teva Pharmaceuticals forecast lower profit but higher sales this year after a strong 2023 fourth quarter boosted by a large upfront payment from Sanofi as part of a collaboration to develop a treatment for inflammatory bowel disease.  Teva said it earned $1.00 per diluted share excluding one-time items in the October-December quarter, up from 71 cents per share a year earlier.  Sanofi, a leader in immunology, in October said it would invest $1.5 billion in the development of Teva's anti-TL1A drug with Teva receiving an upfront payment of $500 million.","url":"https://finance.yahoo.com/news/teva-pharm-profit-handily-beats-131032661.html"},{"category":"company","date":1706705575,"headline":"Teva Pharmaceutical Industries Ltd (TEVA) Reports Solid Growth in 2023 Earnings","id":125429430,"image":"https://media.zenfs.com/en/us.finance.gurufocus/cc15b7d28ff5129d33bebe03603f6c61","symbol":"TEVA","publisher":"Yahoo","summary":"Stabilizing Generics and Innovative Brands Drive Revenue Increase","url":"https://finance.yahoo.com/news/teva-pharmaceutical-industries-ltd-teva-125255762.html"},{"category":"company","date":1706702400,"headline":"Teva Reports Growth in Fourth Quarter and Full Year 2023","id":125429431,"image":"https://media.zenfs.com/en/business-wire.com/3d5d495fa1452bc40c3d748746ce1ffc","symbol":"TEVA","publisher":"Yahoo","summary":"TEL AVIV, Israel, January 31, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2023.","url":"https://finance.yahoo.com/news/teva-reports-growth-fourth-quarter-120000390.html"},{"category":"company","date":1706701020,"headline":"What You Missed On Wall Street This Morning","id":125433814,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3326296418"},{"category":"company","date":1706700761,"headline":"Teva to divest active pharmaceutical ingredient business","id":125429432,"image":"https://media.zenfs.com/en/reuters.com/1e54193db909913913139382a7c9909a","symbol":"TEVA","publisher":"Yahoo","summary":"The API unit, which brought in revenue of $1.05 billion in 2022, makes pharmaceutical ingredients that are used in both generic and branded medicines, and serves over 1,000 clients globally.  Teva is expected to report earnings later on Wednesday.  Teva has been focused on cutting its $35 billion of debt as it fought a spate of lawsuits alleging it helped fuel the U.S. opioid epidemic, and is recovering from the loss of exclusivity for its multiple sclerosis drug Copaxone.","url":"https://ca.finance.yahoo.com/news/teva-divest-active-pharmaceutical-ingredient-113241289.html"},{"category":"company","date":1706700008,"headline":"UPDATE 2-Teva to divest active pharmaceutical ingredient business","id":125429433,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"TEVA","publisher":"Yahoo","summary":"Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient (API) unit to focus on its core business, the world's largest generic drugs maker said on Wednesday.  Teva is expected to report earnings later on Wednesday.  Teva has been focused on cutting its $35 billion of debt as it fought a spate of lawsuits alleging it helped fuel the U.S. opioid epidemic, and is recovering from the loss of exclusivity for its multiple sclerosis drug Copaxone.","url":"https://finance.yahoo.com/news/1-teva-divest-active-pharmaceutical-112008820.html"},{"category":"company","date":1706698800,"headline":"Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy","id":125429434,"image":"https://s.yimg.com/ny/api/res/1.2/ODwG5YqBesqSG4bCHfK4QA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MzE-/https://media.zenfs.com/en/business-wire.com/e4de95951bcb5b48b1a731887f92c2d0","symbol":"TEVA","publisher":"Yahoo","summary":"TEL AVIV, Israel, January 31, 2024--Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or \"TAPI\". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide.","url":"https://finance.yahoo.com/news/teva-announces-intention-divest-api-110000401.html"},{"category":"company","date":1706697480,"headline":"Teva hits 52-week high on outlook, API divestment","id":125441875,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3326201028"},{"category":"company","date":1706696460,"headline":"Teva (NYSE:TEVA) Delivers Q4 Beat; Will Divest API Unit","id":125441900,"image":"","symbol":"TEVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3326175725"},{"category":"company","date":1706695500,"headline":"Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday","id":125431877,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3326151129"},{"category":"company","date":1706692620,"headline":"Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates","id":125441902,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3326078260"},{"category":"company","date":1706689140,"headline":"5 stocks to watch on Wednesday: Boeing, Qualcomm, Teva Pharmaceutical and more","id":125431244,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325992942"},{"category":"company","date":1706687940,"headline":"Teva expects 'stabilization' of generics business in North America in 2024","id":125441904,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325964931"},{"category":"company","date":1706686200,"headline":"Teva (NYSE:TEVA) Delivers Q4 Beat; To Divest API Unit","id":125441905,"image":"","symbol":"TEVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325929298"},{"category":"company","date":1706686020,"headline":"Teva expects 2H24 revenue 'slightly higher' than 1H24","id":125441906,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325923966"},{"category":"company","date":1706685180,"headline":"Teva expects Austedo to achieve $2.5B in sales by 2027","id":125441907,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325906588"},{"category":"company","date":1706683860,"headline":"Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser","id":125431255,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325881768"},{"category":"company","date":1706681760,"headline":"Teva sees FY24 EPS $2.20-$2.50, consensus $2.42","id":125441911,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325843359"},{"category":"company","date":1706681520,"headline":"Teva reports Q4 EPS $1.00, consensus 77c","id":125441912,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325837760"},{"category":"company","date":1706681160,"headline":"Teva Pharmaceutical Non-GAAP EPS of $1.00 beats by $0.24, revenue of $4.46B beats by $450M","id":125437784,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325831863"},{"category":"company","date":1706681160,"headline":"Options Volatility and Implied Earnings Moves Today, January 31, 2024","id":125431265,"image":"","symbol":"TEVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325832210"},{"category":"company","date":1706679000,"headline":"Teva to divest API unit to focus on core business strengths","id":125441917,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325797161"},{"category":"company","date":1706677920,"headline":"Earnings Scheduled For January 31, 2024","id":125431267,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325780640"},{"category":"company","date":1706677380,"headline":"Teva plans to divest its active-pharmaceutical ingredient business","id":125441920,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3325773464"},{"category":"company","date":1706671680,"headline":"What You Missed On Wall Street On Wednesday","id":125441921,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3326684503"},{"category":"company","date":1706613300,"headline":"Stocks Mixed Ahead Of Big Tech Earnings","id":125408303,"image":"","symbol":"TEVA","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3324341761"},{"category":"company","date":1706608380,"headline":"Notable earnings before Wednesday's open","id":125404185,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3324228051"},{"category":"company","date":1706601780,"headline":"A Preview Of Teva Pharmaceutical Indus's Earnings","id":125413142,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3324082531"},{"category":"company","date":1706582880,"headline":"Teva earnings preview: Israeli drugmaker to report early Wednesday","id":125413143,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3324654811"},{"category":"company","date":1706508120,"headline":"Teva price target raised by $1 at BofA, here's why","id":125381662,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3322122920"},{"category":"company","date":1706503920,"headline":"Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?","id":125377239,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3322068071"},{"category":"company","date":1706503860,"headline":"Teva price target raised by $1 at Barclays, here's why","id":125381664,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3322067353"},{"category":"company","date":1706501280,"headline":"Barclays Remains a Buy on Teva Pharmaceutical (TEVA)","id":125381665,"image":"","symbol":"TEVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3322037989"},{"category":"company","date":1706463776,"headline":"50 Most Populated Countries in the World in 2024","id":125369658,"image":"https://media.zenfs.com/en/insidermonkey.com/1448860bbe609cde148ea2cf14a322c9","symbol":"TEVA","publisher":"Yahoo","summary":"In this article, we will look at the 50 most populated countries in the world in 2024. If you want to skip our detailed discussion on population growth and its impact, go ahead to the 15 Most Populated Countries in the World in 2024. Less than 1 billion people lived on Earth for most of […]","url":"https://finance.yahoo.com/news/50-most-populated-countries-world-174256580.html"},{"category":"company","date":1706425260,"headline":"Earnings week ahead: Microsoft, Apple, Meta, Google, Amazon, Chevron and more","id":125364359,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3321250570"},{"category":"company","date":1706278523,"headline":"Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics","id":125330814,"image":"https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653","symbol":"TEVA","publisher":"Yahoo","summary":"Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.","url":"https://finance.yahoo.com/news/unveiling-teva-pharmaceutical-industries-ltd-141523535.html"},{"category":"company","date":1706266800,"headline":"Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's","id":125321960,"image":"https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41","symbol":"TEVA","publisher":"Yahoo","summary":"Amphastar, Teva and Dr. Reddy's have been highlighted in this Industry Outlook article.","url":"https://finance.yahoo.com/news/zacks-industry-outlook-highlights-amphastar-110000183.html"},{"category":"company","date":1706250180,"headline":"PBMs ramp up lobbying efforts amid growing public scrutiny","id":125326124,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3318572051"},{"category":"company","date":1706196900,"headline":"3 Generic Drug Stocks to Watch Amid Improving Market Prospects","id":125318767,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"TEVA","publisher":"Yahoo","summary":"With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.","url":"https://finance.yahoo.com/news/3-generic-drug-stocks-watch-153500433.html"},{"category":"company","date":1706193610,"headline":"Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?","id":125308797,"image":"https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94","symbol":"TEVA","publisher":"Yahoo","summary":"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.","url":"https://finance.yahoo.com/news/investors-undervaluing-teva-pharmaceutical-industries-144010418.html"},{"category":"company","date":1706177220,"headline":"March 8th Options Now Available For Teva Pharmaceutical Industries","id":125350602,"image":"","symbol":"TEVA","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3316878324"},{"category":"company","date":1706163970,"headline":"Teva Pharmaceutical Industries Limited - Depositary Receipt () (TEVA) Price Target Increased by 40443.23% to 12.24","id":125291840,"image":"","symbol":"TEVA","publisher":"Fintel","summary":"","url":"https://fintel.io/news/teva-pharmaceutical-industries-limited-depositary-receipt-teva-price-target-increased-by-4044323-to-1224-519"},{"category":"company","date":1706160000,"headline":"Teva price target raised by $2 at JPMorgan, here's why","id":125304642,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3316516849"},{"category":"company","date":1706075880,"headline":"TEVA Crosses Above Average Analyst Target","id":125304643,"image":"","symbol":"TEVA","publisher":"ETF Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3314628745"},{"category":"company","date":1706073240,"headline":"Teva price target raised by $2 at UBS, here's why","id":125304644,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3314588853"},{"category":"company","date":1706007180,"headline":"Nvidia initiated, Tractor Supply downgraded: Wall Street's top analyst calls","id":125255220,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3313144039"},{"category":"company","date":1705995180,"headline":"Teva raised to Buy at Jefferies citing a positive setup ahead of 2024 outlook","id":125252061,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3312881280"},{"category":"company","date":1705992480,"headline":"Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday","id":125266126,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3312830785"},{"category":"company","date":1705992201,"headline":"ExxonMobil, Duke Energy raised on improving sector valuations: 4 big analyst picks","id":125248998,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"TEVA","publisher":"Yahoo","summary":"Here is your Pro Recap of the biggest analyst picks you may have missed today: upgrades at Exxon Mobil,  Duke Energy  , Zuora, and Teva Pharma.  TD Cowen upgraded  Exxon Mobil  (NYSE:XOM) to Outperform from Market Perform with a price target of $115.00, as reported in real-time on InvestingPro.  The analysts noted that the potential for greater upside has become more attractive, especially since the stock's value has dropped without any change in its valuation.","url":"https://finance.yahoo.com/news/exxonmobil-duke-energy-raised-improving-064321727.html"},{"category":"company","date":1705990020,"headline":"In-Depth Examination Of 4 Analyst Recommendations For Teva Pharmaceutical Indus","id":125304650,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3312788522"},{"category":"company","date":1705987500,"headline":"Corcept Therapeutics price target lowered by $4 at Leerink, here's why","id":125304651,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3312749699"},{"category":"company","date":1705982580,"headline":"Teva just upgraded at Jefferies, here's why","id":125304653,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3312681738"},{"category":"company","date":1705981740,"headline":"Teva Pharmaceutical’s Buy Rating: Growth Prospects from Generic Korlym Launch and Biosimilar Approvals","id":125304654,"image":"","symbol":"TEVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3312670489"},{"category":"company","date":1705980360,"headline":"Bullish Outlook for Teva Pharmaceutical: Santangelo Recommends Buy on Strong Growth and Valuation Expansion Potential","id":125304656,"image":"","symbol":"TEVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3312652244"},{"category":"company","date":1705975380,"headline":"Watch GSK amid evidence hearing on Zantac litigation","id":125259317,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3313422204"},{"category":"company","date":1705952734,"headline":"Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch","id":125229430,"image":"https://media.gettyimages.com/id/1444892930/es/foto/human-genome-analysis-dna-molecular-structure.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=umrPn7rb2HgD66Gbo-Mt_-ja8G8Y8Fjt9VJPNa89xO4=","symbol":"TEVA","publisher":"SeekingAlpha","summary":"Catalyst Pharmaceuticals' diverse product portfolio and key catalysts could impact its revenue, but its current valuation suggests a hold for now. Read more here.","url":"https://seekingalpha.com/article/4664277-catalyst-pharmaceuticals-stock-firdapse-litigation-agamrees-launch"},{"category":"company","date":1705923420,"headline":"10 Health Care Stocks Whale Activity In Today's Session","id":125218903,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3311390359"},{"category":"company","date":1705681260,"headline":"Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx","id":125176962,"image":"https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1","symbol":"TEVA","publisher":"Yahoo","summary":"Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.","url":"https://finance.yahoo.com/news/exelixis-exel-reports-positive-eu-162100634.html"},{"category":"company","date":1705666980,"headline":"Healthcare Giant Eli Lilly Under FDA Lens Again For Manufacturing Lapses","id":125181649,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3307957147"},{"category":"company","date":1705595040,"headline":"Exelixis Says European Patent Office Ruled in Favor of Cancer-Treatment Patent","id":125188196,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"TEVA","publisher":"MarketWatch","summary":"By Sabela Ojea Exelixis said the Opposition Division of the European Patent Office ruled in favor of its patent for tablet formulations of cabozantinib, a...","url":"https://www.marketwatch.com/story/exelixis-says-european-patent-office-ruled-in-favor-of-cancer-treatment-patent-55687171"},{"category":"company","date":1705547340,"headline":"EPO rules in favor of Exelixis on patent covering Cabometyx","id":125141777,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3306467180"}]}